Karuna Therapeutics Inc. (KRTX) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Birkenstock surges on revenue beat, higher full-year outlook
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Karuna Therapeutics Inc. (KRTX) PT Raised to $260 at Stifel
August 8, 2022 3:59 PM EDTStifel analyst Paul Matteis raised the price target on Karuna Therapeutics Inc. (NASDAQ: KRTX) to $260.00 (from $185.00) while maintaining a Buy rating.
The analyst comments "We rate KRTX shares Buy. Karuna is a biotechnology company focused on the development of novel neuroscience... More
